Product Pathways - Apoptosis / Autophagy
Bcl-xL Antibody #2762
| Applications | Reactivity | Sensitivity | MW (kDa) | Source |
|---|---|---|---|---|
| W IP IHC-P | H M R Mk | Endogenous | 30 | Rabbit |
Applications Key:
W=Western Blotting
IP=Immunoprecipitation
IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key:
H=Human
M=Mouse
R=Rat
Mk=Monkey
Species cross-reactivity is determined by Western blot.
Specificity / Sensitivity
Bcl-xL Antibody detects endogenous levels of total Bcl-xL protein. The antibody does not cross-react with other Bcl-2 family members.
Source / Purification
Polyclonal antibodies are produced by immunizing rabbits with a synthetic peptide (KLH coupled) corresponding to residues surrounding Asp61 of human Bcl-xL. Antibodies are purified by protein A and peptide affinity chromatography.
Western Blotting
Western blot analysis of extracts from Jurkat (human), NIH/3T3 (mouse) or C6 (rat) cells, untreated or etoposide-treated (25 µM, Jurkat) or staurosporine-treated (1 µM, NIH/3T3 and C6), using Bcl-xL Antibody.
IP
Immunoprecipitation of Bcl-xL from Jurkat cell extracts, using Bcl-xL Antibody. Lane 1 is the lysate control; lane 2 is antibody alone and lane 3 is antibody plus lysate.
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human endodermal sinus tumor of the ovary, using Bcl-xL Antibody.
Background
Bcl-xL prevents apoptosis through two different mechanisms: by heterodimerization with an apoptotic protein to inhibit its apoptotic effect (1,2), and by its direct pore-forming effect on the outer membrane of mitochondria which helps maintain a normal membrane state under stress conditions (3). Bcl-xL is phosphorylated by JNK following treatment with microtubule-damaging agents such as paclitaxel, vinblastine and nocodazole (4,5).
- Adams, J.M. and Cory, S. (1998) Science 281, 1322-1326.
- Minn, A.J. et al. (1999) EMBO. J. 18, 632-643.
- Vander Heiden, M.G. et al. (2001) J. Biol. Chem. 276, 19414-19419.
- Fan, M. et al. (2000) J. Biol. Chem. 275, 29980-29985.
- Poruchynsky, M.S. et al. (1998) Cancer Res. 58, 3331-3338.
Application References
- Su, F. et al. (2002) WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev. 16 (1), 46-57. This article references the use of Bcl-xL Antibody in the following applications: Western Blotting
- Saito, A. et al. (2003) Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway. J. Neurosci. 23, 1710-1718. This article references the use of Bcl-xL Antibody in the following applications: IHC-FL (floating/frozen) Western Blotting
- Leu, J. I. et al. (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell. Biol. 6, 443-450. This article references the use of Bcl-xL Antibody in the following applications: IP Western Blotting
- Yang, C. C. et al. (2003) Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J. Biol. Chem. 278, 25872-25878. This article references the use of Bcl-xL Antibody in the following applications: Western Blotting
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 2002 BID Antibody (Human Specific)
- 2003 BID Antibody (Mouse Specific)
- 2772 Bax Antibody
- 4521 Bok Antibody
- 4592 Bik Antibody
- 9292 Bad Antibody
- 6320 SignalSilence® Bax siRNA Kit
- 6321 SignalSilence® Bax siRNA
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 1225 Bcl-xL Blocking Peptide
This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.